...
首页> 外文期刊>Journal of Surgical Oncology >Prognostic relevance of androgen receptor detection in operable breast cancer.
【24h】

Prognostic relevance of androgen receptor detection in operable breast cancer.

机译:可手术乳腺癌中雄激素受体检测的预后相关性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND AND OBJECTIVES: Androgen receptor (AR) is relevant for prognostication in breast cancer. Different determination methods and cut-off levels hamper interpretation and comparisons of studies. Long-term prognostic evaluation of different AR assays in patients comprising operable breast cancers is scarce. METHODS: AR was evaluated in 120 primary tumors using the dextran-coated charcoal method (charc-AR), and quantitative immunohistochemistry (IHC) on whole sections (WS) and tissue microarrays (TMA). Nuclear and cytoplasmic-AR localization was determined, and the prognostic importance of AR assays was assessed. Comparisons and correlations with the mitotic activity index (MAI), estrogen receptor (ERalpha), progesterone receptor (PR), HER-2, and histological grade (WHO I-III) were made. RESULTS: Nuclear-AR in WS, but not charc-AR, strongly correlated with MAI (P = 0.001). However, prognostic information appeared in univariate survival analyses only. Nuclear-AR in TMA was not prognostic. Charc-AR was independent prognostic in node positives both for relapse free survival (RFS) and breast cancer specific survival (BCSS). Both charc-AR and IHC cytoplasmic-AR provided independent prognostic survival information for BCSS in women <55 years. CONCLUSION: Methods that can detect AR localized in the cytoplasm yield important prognostic information, and further studies in patients with operable breast cancer are warranted.
机译:背景与目的:雄激素受体(AR)与乳腺癌的预后有关。不同的测定方法和临界水平阻碍了研究的解释和比较。缺乏对包括可手术性乳腺癌的患者进行不同AR分析的长期预后评估。方法:使用葡聚糖包被的木炭法(charc-AR)以及整个切片(WS)和组织微阵列(TMA)的定量免疫组织化学(IHC)评估了120例原发性肿瘤中的AR。确定了核和细胞质AR的定位,并评估了AR分析的预后重要性。与有丝分裂活性指数(MAI),雌激素受体(ERalpha),孕激素受体(PR),HER-2和组织学分级(WHO I-III)进行比较和相关。结果:WS中的核AR与char-AR无关,与MAI密切相关(P = 0.001)。但是,预后信息仅出现在单变量生存分析中。 TMA中的核抗-AR不能预后。 Charc-AR在无复发生存期(RFS)和乳腺癌特异性生存期(BCSS)的淋巴结阳性中是独立的预后指标。 charc-AR和IHC胞质AR均为55岁以下女性的BCSS提供了独立的预后生存信息。结论:可检测AR定位于细胞质中的方法可提供重要的预后信息,因此有必要对可手术乳腺癌患者进行进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号